References
1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–34. DOI: https://doi.org/10.1038/nrmicro.2016.81
2. Yang L., Tian D., Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao. 2020; 36 (4): 593–604. DOI: https://doi.org/10.13345/j.cjb.200094 (in Chinese)
3. McCreary E.K., Pogue J.M. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020; 7 (4): ofaa105. DOI: https://doi.org/10.1093/ofid/ofaa105
4. Giovane R.A., Rezai S., Cleland E., Henderson C.E. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: a review. Rev Med Virol. 2020; e2136. DOI: https://doi.org/10.1002/rmv.2136
5. Mitjà O., Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020; 8: e639–e640. DOI: https://doi.org/10.1016/S2214-109X(20)30114-5
6. Wu R., Wang L., Kuo H.D., et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020; 6: 56–70. DOI: https://doi.org/10.1007/s40495-020-00216-7
7. Esposito S., Noviello S., Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020; 28 (2): 198–211.
8. Bhimraj A., Morgan R.L., Shumaker A.H., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 [published online ahead of print, 2020 Apr 27]. Clin Infect Dis. 2020; ciaa478. DOI: https://doi.org/10.1093/cid/ciaa478
9. Kalil A.C. Treating COVID-19-off-label drug use, compassionate use, and Randomized clinical trials during pandemics. JAMA. 2020. 323 (19): 1897–8. DOI: https://doi.org/10.1001/jama.2020.4742
10. Wang Y., Zhang D., Du G., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020; 395 (10238): 1694]. Lancet. 2020; 395 (10236): 1569–78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9
11. Cao B., Wang Y., Wen D., et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382 (19): 1787–99. DOI: https://doi.org/10.1056/NEJMoa2001282
12. Zhu Z., Lu Z., Xu T., et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81 (1): e21–e23. DOI: https://doi.org/10.1016/j.jinf.2020.03.060
13. Hung I.F., Lung K.C., Tso E.Y., et al. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patient s admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395 (10238): 1695–1704. DOI: https://doi.org/10.1016/S0140-6736(20)31042-4
14. Zhou Q., Chen V., Shannon C.P., et al. Interferon-a2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. DOI: https://doi.org/10.3389/fimmu.2020.01061
15. Ippolito M., Giarratano A., Einav S. A systematic review onthe efficacy and safety of chloro-quine for the treatment ofCOVID-19. J Crit Care. 2020; 57: 279-83. DOI: https://doi.org/10.1016/j.jcrc.2020.03.005
16. Chen C., et al. Favipiravir versus arbidol for COVID-19: arandomized clinical trial. medRxiv. 2020: 2020.03.17.20037432. DOI: https://doi.org/10.1101/2020.03.17.20037432
17. Cai Q., Yang M., Liu D., et al. Experimental treatment withfavipiravir for COVID-19: an open-label control study. Engineering. 2020. DOI: https://doi.org/10.1016/j.eng2020.03.007
18. Временные методические рекомендации (ВМР) Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», версия 7 от 03.06.2020. [Temporary guidelines of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version from June 3, 2020. (in Russian)]
19. COVID-19 Therapeutic trial synopsis, draft February 18, 2020. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_syn-opsis_Final_18022020.pdf
20. Inui S., Fujikawa A., Jitsu M., et al. Chest CT findings in cases from the cruise ship «Dia-mond Princess» with Coronavirus Disease 2019 (COVID-19). Radiology: Cardiothoracic Imaging. 2020; 2: e200110. DOI: https://doi.org/10.1148/ryct.2020200110
21. Chen J., Qi T., Liu L., et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020; 80 (5): e1-e6. DOI: https://doi.org/10.1016/jjinf.2020.03.004
22. Wu J., Li W., Shi X., et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020; 288 (1): 128-8. DOI: https://doi.org/10.1111/joim.13063
23. Письмо Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 13.06.2019 № 2/8515-2019-32 «Об итогах эпидемического сезона по гриппу и ОРВИ 2018-2019 гг. и задачах на 2019-2020 гг.» [Letter of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare dated June 13, 2019 No. 2/8515-2019-32 ”On the results of the epidemic season for influenza and SARS in 2018-2019 and tasks for 2019-2020”. (in Russian)]
24. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: 107512. DOI: 10.1016/j.pharmthera.2020.107512
25. Preliminary report of the favipiravir observational study in Japan - 2020/5/15-Fa-vipiravir Observational Study Group. Available from: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf